This protocol addresses newly diagnosed epilepsy with generalized tonic-clonic seizures alone — a condition in which timely therapeutic intervention is critical to reducing the high risk of seizure recurrence seen in untreated patients.
Management centers on the prompt initiation of antiseizure medication monotherapy upon diagnosis. Which agent is selected — and the individualized criteria guiding that choice — are detailed in the full structured protocol.
The primary treatment target is the absence of generalized tonic-clonic seizure recurrence, assessed over the first year of treatment.
DOI: 10.1002/epi4.12981
Our results underscore the importance of initiating prompt ASM treatment upon EGTCA diagnosis, given the high recurrence rate in untreated patients.
In the treated group, all recurrences occurred during the first year of treatment.
View source ↗